A Novel RANKL-Targeted Furoquinoline Alkaloid Ameliorates Bone Loss in Ovariectomized Osteoporosis through Inhibiting the NF-<i>κ</i>B Signal Pathway and Reducing Reactive Oxygen Species

<div>A total of 139 upregulated genes and 420 downregulated genes were identified in RNA-seq (a). GO enrichment analysis based on biological processes (BPs), molecular functions (MFs), and cellular components (CCs) was performed to gain insights into the physical part (b). Furthermore, KEGG pathway analysis was performed to identify the top 20 signaling pathways affected by differentially expressed genes (c). KEGG pathway annotation indicated that multiple genes were enriched in signal transduction and signaling molecules and interactions, confirming the KEGG enrichment findings (d). A PPI network of coregulated downregulated genes was obtained and visualized (e).</div>

Oxidative Medicine and Cellular Longevity

fig2

Figure 2

Figure 2: A Novel RANKL-Targeted Furoquinoline Alkaloid Ameliorates Bone Loss in Ovariectomized Osteoporosis through Inhibiting the NF-<i>κ</i>B Signal Pathway and Reducing Reactive Oxygen Species 

Figure 2 | A Novel RANKL-Targeted Furoquinoline Alkaloid Ameliorates Bone Loss in Ovariectomized Osteoporosis through Inhibiting the NF-κB Signal Pathway and Reducing Reactive Oxygen Species 